文献速递眼底病与葡萄膜炎

私人保险与Medicare Advantage参保者眼科抗血管内皮生长因子使用趋势

Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
PubMed 文献 · Ophthalmology · 2016-11-24

该回顾性队列研究利用2006年1月1日至2015年12月31日行政索赔数据,分析美国124 835例18岁及以上患者共959 945次玻璃体内抗VEGF注射。贝伐珠单抗占64.6%,年龄相关性黄斑变性(AMD)占62.7%;贝伐珠单抗和雷珠单抗用于AMD在2011/2012年后下降,阿柏西普上升。

要点

  • 贝伐珠单抗是最常用抗VEGF药物(占64.6%),尽管未获FDA批准用于眼科疾病。
  • AMD是最常见治疗疾病(占62.7%),其次为糖尿病视网膜疾病(16.1%)和视网膜静脉阻塞(8.3%)。
  • 雷珠单抗使用在2014年后下降,贝伐珠单抗和阿柏西普的绝对与相对使用均增加。

核心结论

  • 玻璃体内抗VEGF药物注射从2006年至2015年逐年增加。
  • 贝伐珠单抗是最常用药物,尽管其缺乏美国FDA批准用于治疗眼科疾病,AMD是最常见治疗疾病。
  • 雷珠单抗使用在2014年后下降,而贝伐珠单抗和阿柏西普的绝对与相对使用均增加。

研究设计与样本

  • 回顾性队列研究,使用2006年1月1日至2015年12月31日行政索赔数据。
  • 共纳入美国124 835例18岁及以上患者。
  • 使用OptumLabs Data Warehouse识别接受玻璃体内抗VEGF注射的患者。

主要发现

  • 2006年至2015年共124 835例患者接受959 945次抗VEGF注射。
  • 所有注射中贝伐珠单抗占64.6%,雷珠单抗占22.0%,阿柏西普占13.4%。
  • AMD治疗占62.7%,糖尿病视网膜疾病占16.1%(其中增殖性糖尿病视网膜病变占所有注射的0.9%),视网膜静脉阻塞占8.3%,其他用途占12.9%。
  • AMD患者中,贝伐珠单抗和雷珠单抗注射在2011/2012年后下降(2006年分别为58.8和35.3次/1000例AMD患者,2015年分别为294.4和100.7次/1000),阿柏西普上升(2011年1.1次/1000例AMD患者至2015年183.0次/1000)。
  • 糖尿病视网膜疾病患者中,贝伐珠单抗注射逐年增加(2009年2.4次/1000例糖尿病视网膜疾病患者至2015年13.6次/1000),雷珠单抗先显著增加后于2014年后下降(2009年0.1至2015年4.0)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the first 10 years of intravitreal anti-vascular endothelial growth factor (VEGF) medication use for ophthalmic disease, including bevacizumab, ranibizumab, and aflibercept. DESIGN: A retrospective cohort study using administrative claims data from January 1, 2006 to December 31, 2015. SUBJECTS: Total of 124 835 patients 18 years of age or over in the United States. METHODS: OptumLabs Data Warehouse, which includes administrative claims data for over 100 million commercially insured and Medicare Advantage individuals, was used to identify patients receiving intravitreal anti-VEGF injections based on Current Procedural Terminology codes. MAIN OUTCOME MEASURES: Total and annual numbers of intravitreal anti-VEGF injections, as well as injections per 1000 enrolled patients per general category of ophthalmic disease, overall and for each available medication. RESULTS: There were 959 945 anti-VEGF injections among 124 835 patients from 2006 to 2015. Among all injections, 64.6% were of bevacizumab, 22.0% ranibizumab, and 13.4% aflibercept; 62.7% were performed to treat age-related macular degeneration (AMD), 16.1% to treat diabetic retinal diseases (including 0.9% of all injections that were for proliferative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses. Use of bevacizumab and ranibizumab for AMD plateaued as of 2011/2012 and decreased thereafter (in 2006, 58.8 and 35.3 injections/1000 AMD patients, respectively; in 2015, 294.4 and 100.7 injections/1000), whereas use of aflibercept increased (1.1 injections/1000 AMD patients in 2011 to 183.0 injections/1000 in 2015). Bevacizumab use increased each year for diabetic retinal disease (2.4 injections/1000 patients with diabetic retinal disease in 2009 to 13.6 per 1000 in 2015) while that of ranibizumab initially increased significantly and then declined after 2014 (0.1 in 2009 to 4.0 in 2015). Aflibercept use increased each year in patients with diabetic retinal diseases and retinal vein occlusions (both <0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 in 2015). CONCLUSIONS: Intravitreal injections of anti-VEGF medications increased annually from 2006 to 2015. Bevacizumab was the most common medication used, despite its lacking U.S. Food and Drug Administration approval to treat ophthalmic disease, and AMD was the most common condition treated. Ranibizumab use declined after 2014 while both the absolute and relative use of bevacizumab and aflibercept increased.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Parikh R, Ross JS, Sangaralingham LR, et al. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Ophthalmology. 2016. PMID: 27890437. doi:10.1016/j.ophtha.2016.10.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。